# A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP)

> **NCT04925141** · PHASE4 · COMPLETED · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 62 (actual)

## Conditions studied

- Chronic Myelogenous Leukemia - Chronic Phase

## Interventions

- **DRUG:** Dasatinib Tablets

## Key facts

- **NCT ID:** NCT04925141
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-10
- **Primary completion:** 2018-10-22
- **Final completion:** 2019-12-06
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2021-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04925141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04925141, "A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04925141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*